Organogenesis Holdings Inc. (ORGO) Financial Statements (2024 and earlier)

Company Profile

Business Address 85 DAN ROAD
CANTON, MA 02021
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments88,91788,694102,478107,250112,279107,897
Cash and cash equivalents88,91788,694102,478107,250112,279107,897
Restricted cash and investments591721812771665605
Receivables93,61592,02189,45093,11588,82479,477
Inventory, net of allowances, customer advances and progress billings25,36425,53924,78324,68323,23522,737
Inventory25,36425,53924,78324,68323,23522,737
Prepaid expense7,9489,8475,0864,7076,5407,135
Total current assets:216,435216,822222,609230,526231,543217,851
Noncurrent Assets
Operating lease, right-of-use asset43,54442,83943,19245,36945,86047,468
Property, plant and equipment111,825106,637102,46397,01293,29284,268
Intangible assets, net (including goodwill)47,10248,33249,56150,78252,00353,224
Goodwill28,77228,77228,77228,77228,77228,772
Intangible assets, net (excluding goodwill)18,33019,56020,78922,01023,23124,452
Deferred income tax assets30,01430,01430,01431,99431,99431,994
Other noncurrent assets1,3931,4631,5201,5891,6651,467
Total noncurrent assets:233,878229,285226,750226,746224,814218,421
TOTAL ASSETS:450,313446,107449,359457,272456,357436,272
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities55,17458,90758,77758,95558,47460,354
Employee-related liabilities21,00322,101
Accounts payable27,39030,31032,33037,95236,37327,935
Accrued liabilities27,78428,59726,447  32,419
Debt5,6895,0094,5385,0043,5963,227
Restructuring reserve2981,0871,192  132
Other undisclosed current liabilities12,29411,07310,51625,31426,16013,079
Total current liabilities:73,45576,07675,02389,27388,23076,792
Noncurrent Liabilities
Long-term debt and lease obligation63,89164,86066,231110,581112,669115,192
Long-term debt, excluding current maturities63,48964,86066,23167,60068,96969,869
Finance lease, liability402     
Liabilities, other than long-term debt41,68541,47042,4361,0901,0731,060
Other liabilities1,1901,1451,1221,0901,0731,060
Operating lease, liability40,49540,32541,31442,98143,70045,323
Total noncurrent liabilities:105,576106,330108,667111,671113,742116,252
Total liabilities:179,031182,406183,690200,944201,972193,044
Equity
Equity, attributable to parent271,282263,701265,669256,328254,385243,228
Common stock131313131313
Additional paid in capital314,838312,573310,957309,102307,374303,261
Accumulated deficit(43,569)(48,885)(45,301)(52,787)(53,002)(60,046)
Total equity:271,282263,701265,669256,328254,385243,228
TOTAL LIABILITIES AND EQUITY:450,313446,107449,359457,272456,357436,272

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues117,316107,642115,516116,859121,40198,117
Cost of revenue(26,316)(26,607)(27,110)(26,177)(26,652)(25,080)
Gross profit:91,00081,03588,40690,68294,74973,037
Operating expenses(81,255)(85,036)(79,688)(88,903)(82,814)(72,165)
Operating income (loss):9,745(4,001)8,7181,77911,935872
Nonoperating income (expense)(566)(626)36(567)(751)(740)
Other nonoperating income (expense)282365(21)(3)
Interest and debt expense(594)(649)30(572)(730)(737)
Income (loss) from continuing operations before equity method investments, income taxes:8,585(5,276)8,78464010,454(605)
Other undisclosed income (loss) from continuing operations before income taxes594649(30)572730737
Income (loss) from continuing operations before income taxes:9,179(4,627)8,7541,21211,184132
Income tax expense (benefit)(3,863)1,658(1,268)(997)(2,440)(45)
Income (loss) from continuing operations:5,316(2,969)7,4862158,74487
Income before gain (loss) on sale of properties:2158,74487
Net income (loss) available to common stockholders, diluted:5,316(2,969)7,4862158,74487

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net income (loss):5,316(2,969)7,4862158,74487
Comprehensive income (loss), net of tax, attributable to parent:5,316(2,969)7,4862158,74487

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: